Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMETHYST LTE long-term extension of litifilimab in cutaneous lupus erythematosus
2023-504863-17-00Phase 3Authorised
- Sponsor
- Biogen
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 29
01
Overview
Phase 3, open-label, single-arm trial of litifilimab in subacute cutaneous lupus erythematosus (SCLE) and discoid lupus erythematosus (DLE), sponsored by Biogen. Primary endpoint: Number of participants with treatment-emergent adverse events and serious adverse events. Planned start Dec 2023; status: authorised.
02
Drugs
litifilimab
03
Conditions
subacute cutaneous lupus erythematosus (SCLE)discoid lupus erythematosus (DLE)
Beyond the preview
Go deeper on 2023-504863-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504863-17-00.